TY - JOUR T1 - A retrospective audit to assess the safety and efficacy of apremilast use in chronic plaque psoriasis JF - Future Healthcare Journal JO - Future Healthc J SP - s47 LP - s48 DO - 10.7861/fhj.7.1.s47 VL - 7 IS - Suppl 1 AU - Katie Kwan AU - Jui Vyas Y1 - 2020/02/01 UR - http://www.rcpjournals.org/content/7/Suppl_1/s47.abstract N2 - Apremilast is a small molecule inhibitor of phosphodiesterase 4, an intracellular enzyme which modulates the expression of cytokines and mediators including tumour necrosis factor α and interleukin 23.1 It was licensed for use by the European Commission in 2015 and, following a recent review, the National Institute for Health and Care Excellence (NICE) has also recommended it as a treatment option for patients with severe plaque psoriasis from November 2016. The purpose of this audit was to assess the safety and efficacy of apremilast use in adult patients with moderate to severe plaque psoriasis.Retrospective analysis was conducted using individual patient … ER -